%0 Journal Article
%@ 1471-2334
%A Hamed, Sonja
%A Behnes, Michael
%A Pauly, Dominic
%A Lepiorz, Dominic
%A Barre, Max
%A Becher, Tobias
%A Lang, Siegfried
%A Akin, Ibrahim
%A Borggrefe, Martin
%A Bertsch, Thomas
%A Hoffmann, Ursula
%C London; Berlin; Heidelberg
%D 2017
%F heidok:23338
%I BioMed Central; Springer
%J BMC Infectious Diseases
%N 554
%P 1-10
%T Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions
%U https://archiv.ub.uni-heidelberg.de/volltextserver/23338/
%V 17
%X Background: Pentraxin-3 (PTX-3) is an acute-phase protein involved in inflammatory and infectious processes. This study assesses its diagnostic and prognostic value in patients with sepsis or septic shock in a medical intensive care unit (ICU).   Methods: The study includes 213 ICU patients with clinical criteria of sepsis and septic shock. 77 donors served as controls. Plasma levels of PTX-3, procalcitonin (PCT) and interleukin-6 were measured on day 1, 3 and 8.   Results: PTX-3 correlated with higher lactate levels as well as with APACHE II and SOFA scores (p = 0.0001). PTX-3 levels of patients with sepsis or septic shock were consistently significantly higher than in the control group (p ≤ 0.001). Plasma levels were able to discriminate sepsis and septic shock significantly on day 1, 3 and 8 (range of AUC 0.73–0.92, p = 0.0001). Uniform cut-off levels were defined at ≥5 ng/ml for at least sepsis, ≥9 ng/ml for septic shock (p = 0.0001).   Conclusion: PTX-3 reveals diagnostic value for sepsis and septic shock during the first week of intensive care treatment, comparable to interleukin-6 according to latest Sepsis-3 definitions.   Trial registration: NCT01535534. Registered 14.02.2012